Ernexa Therapeutics effects 1-for-25 reverse stock split, effective May 4, 2026

Ernexa Therapeutics Inc.

Reverse stock split at 1-for-25 ratio; trading on split-adjusted basis began at market open on May 4, 2026.
Certificate of Amendment filed with Delaware Secretary of State on May 1, 2026.
New CUSIP number for common stock post-split: 114082407.
Common stock (ERNA) and warrants (ERNAW) trade on Nasdaq under split-adjusted terms.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Ernexa Therapeutics Inc.: Effected a 1-for-25 reverse stock split of common stock via certificate of amendment to the Restated Certificate of Incorporation (effective 2026-05-04).

Change: charter amendment
Effective: 2026-05-04

Exact text from the filing

On May 1, 2026, Ernexa Therapeutics Inc. (the “Company”), filed a certificate of amendment (the “ Certificate of Amendment ”) to the Company’s Restated Certificate of Incorporation, as amended with the Secretary of State of Delaware to effect a reverse stock split of the Company’s common stock at a ratio of 1-for-25 (the “ Reverse Stock Split ”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-021112

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.